Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02956265
Other study ID # 2016-05-CHRMT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2016
Est. completion date March 25, 2021

Study information

Verified date June 2021
Source Centre Hospitalier Régional Metz-Thionville
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Actinic keratosis are of utmost medical and economical interest because of their high prevalence (20 % of 60 year-old people and older in the Northern hemisphere) and their important cosmetic impact as such actinic keratosis mostly appear on photo-exposed skin sites. The surgeon in charge of such lesions' removal (i) some actinic keratosis adjoining carcinoma to be resected therefore causing the problem of functional areas damaging (eyelids, lips, etc.) or (ii) numerous actinic keratosis localized away from carcinoma (photo-carcinogenesis field) faces the issue of clinical evaluation of such lesions: which ones will spontaneously regress (it is supposed to be the case for 20 % of such lesions);which ones will remain and which ones will develop into invasive carcinomas ? A non-invasive, non-traumatic, automated and real-time help for the clinical diagnosis orientation of such skin lesions could help improving diagnosis accuracy of the medical practitioner's visual inspection: - In terms of sensitivity in order to potentially decrease the number of actinic keratosis evolving towards invasive carcinoma, - In terms of specificity in order to potentially decrease useless resections and reduce resection margins and therefore reduce scars surface.


Recruitment information / eligibility

Status Completed
Enrollment 142
Est. completion date March 25, 2021
Est. primary completion date March 25, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults, and - Autonomous: enjoying full citizenship rights and full mental abilities, and - Affiliated to a social security system, and - Suffering from carcinomatous or polymorphous skin lesions that can be fully managed in an outpatient (ambulatory) surgery procedure. Exclusion Criteria: - Carcinomatous or polymorphous skin lesions that require day admission, or - Carcinomatous or polymorphous skin lesions for which resection margins are uncertain, or - Naevomatous skin lesions and related skin pathologies.

Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Carcinomatous or Polymorphous Skin Lesions

Intervention

Device:
bimodal optical spectroscopy
an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra

Locations

Country Name City State
France CHR Metz Thionville Metz

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Régional Metz-Thionville University of Lorraine

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Optical spectroscopy's diagnostic validity for the 4 histological classes discrimination day 1
Secondary Statistical significance degree of the discrimination by molecular profiling (transcriptomic characterization) between in situ carcinoma (ISC) and invasive carcinoma (InvC). day 1
Secondary Statistical significance degree of the discrimination by molecular profiling (transcriptomic characterization) between 2 classes of actinic keratosis (AK) of clinical relevance: AK characterized by a "low" versus a "high" invasiveness risk day 1
Secondary - Sensitivity and specificity of optical spectroscopy for discriminating the é molecular classes of actinic keratosis: AK characterized by a "low" versus a "high" invasiveness risk. day 1